Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387433 | 1.00 | MAPK14 (1.00) | MAPK14NR3C2MAPK10MAPK13MAPK12 | |
| SCHEMBL21631838 | 0.91 | MAPK14 (0.83) | MAPK14NR3C2 | |
| SCHEMBL2778903 | 0.84 | MAPK14 (0.73) | MAPK14NR3C2 | |
| SCHEMBL6708437 | 0.83 | MAPK14 (0.71) | MAPK14NR3C2MAPK13MAPK12MAPK11 | |
| SCHEMBL3270030 | 0.83 | MAPK14 (0.71) | MAPK14NR3C2MAPK10MAPK13MAPK12 | |
| SCHEMBL6984697 | 0.82 | MAPK14 (0.69) | MAPK14NR3C2MAPK13MAPK12MAPK11 | |
| SCHEMBL6753238 | 0.81 | MAPK14 (0.68) | MAPK14NR3C2MAPK10MAPK13MAPK12 | |
| SCHEMBL4538602 | 0.80 | MAPK14 (0.66) | MAPK14NR3C2MAPK13MAPK12MAPK11 | |
| SCHEMBL1387318 | 0.80 | MAPK14 (0.66) | MAPK14NR3C2MAPK13MAPK12MAPK11 | |
| SCHEMBL4537373 | 0.80 | MAPK14 (0.66) | MAPK14NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7479501-B2 | Heteroaryl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2009-01-20 | — | — | US | disclosed |
| US-20050090501-A1 | Heteroaryl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| EP-1140916-B1 | HETEROARYL-CYCLIC ACETALS | AVENTIS PHARMA LTD (GB) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090501-A1 | Heteroaryl-cyclic acetals | TNF, TNFRSF1A, CD40 | MAPK14 3415/4885NR3C2 192/4885MAPK10 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.